Brain Health Registry Cognitive Assessment Partner

RNS Number : 5604B
Cambridge Cognition Holdings PLC
11 June 2021
 

 

Cambridge Cognition Holdings Plc

(" Cambridge Cognition"   or the "Company")

 

Cambridge Cognition to join the Brain Health Registry as cognitive assessment partner

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer's disease, Parkinson's disease, depression, post-traumatic stress disorder, and other brain disorders.

 

One of the key barriers facing treatment development for neurological and psychiatric conditions is difficulty recruiting the right patients into clinical trials and identifying these individuals at the very early stages of disease progression. In efforts to address this issue researchers at UCSF established the Brain Health Registry: an online enrolment platform for adults who are interested in participating in brain research.

 

Adults aged 18+ years who are interested in participating in research studies can enrol in the Brain Health Registry through the website: https://my.brainhealthregistry.org/BHR/register . This secure, online platform is then used to deliver baseline questions on health, lifestyle and medical history. To build a full and sustained picture of function over an individual's lifespan, participants are also asked to complete web-based questionnaires and cognitive assessments every 6 months: including the CANTABTM Paired Associates Learning task.

 

By regularly assessing healthy adults the Brain Health Registry is building a unique and important resource on functional change over time. This data will be used to identify potential candidates for clinical trials and establish novel biomarkers to detect early stages of brain disorders. This could be beneficial for Cambridge Cognition in providing more real-world data on the use of the assessment and potentially a cohort of patients already assessed with a CANTAB™ test that could be used for a clinical trial.

 

For further information on the Brain Health Registry visit https://www.brainhealthregistry.org/

 

Prof Michael Weiner, Lead Scientific Investigator at the Brain Health Registry, said:

"Accurate cognitive assessment is essential for the online Brain Health Registry to achieve its intended purpose: speeding up the discovery of effective treatments for brain disorders. Cambridge Cognition is joining us as a cognitive assessment partner helping us to speed up the discovery of effective treatments for brain disorders with their validated computerized cognitive assessments."  

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"One of the key challenges facing drug development is identifying which patients are most likely to benefit from a therapeutic intervention. The Brain Health Registry set up a web-based solution to tackle this issue: an online platform to longitudinally monitor adults who are interested in participating in research. The goal of our partnership is to assist the Brain Health Registry in bringing effective treatments for brain disorders by using our cognitive assessments." 

 

For further information, contact:

 

Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Michael Holton, Chief Financial Officer

Tel: 012 2381 0700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAPKEFAPFEFA
UK 100

Latest directors dealings